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Background: Recognizing the rapidly increasing interest and evidence in using metastasis-directed radio-
therapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO convened a committee to establish
consensus regarding definitions of OMD and define gaps in current evidence.
Methods: A systematic literature review focused on curative intent MDRT was performed in Medline,
Embase and Cochrane. Subsequent consensus opinion, using a Delphi process, highlighted the current
state of evidence and the limitations in the available literature.
Results: Available evidence regarding the use of MDRT for OMDmostly derives from retrospective, single-
centre series, with significant heterogeneity in patient inclusion criteria, definition of OMD, and outcomes
reported. Consensus was reached that OMD is largely independent of primary tumour, metastatic loca-
tion and the presence or length of a disease-free interval, supporting both synchronous and metachro-
nous OMD. In the absence of clinical data supporting a maximum number of metastases and organs to
define OMD, and of validated molecular biomarkers, consensus supported the ability to deliver safe
and clinically meaningful radiotherapy with curative intent to all metastatic sites as a minimum require-
ment for defining OMD in the context of radiotherapy. Systemic therapy induced OMD was identified as a
distinct state of OMD. High-resolution imaging to assess and confirm OMD is crucial, including brain
imaging when indicated. Minimum common endpoints such as progression-free and overall survival,
local control, toxicity and quality-of-life should be reported; uncommon endpoints as deferral of systemic
therapy and cost were endorsed.
Conclusion: While significant heterogeneity exists in the current OMD definitions in the literature, con-
sensus was reached on multiple key questions. Based on available data, OMD can to date be defined as
1–5 metastatic lesions, a controlled primary tumor being optional, but where all metastatic sites must
be safely treatable. Consistent definitions and reporting are warranted and encouraged in ongoing trials
and reports generating further evidence to optimize patient benefits.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 148 (2020) 157–166 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Almost 25 years after the first description of an intermediate
state between localised cancer and wide-spread metastatic dis-
ease, termed ‘the oligometastatic state’, the treatment of oligome-
tastatic disease (OMD) with curative intent has been gaining
increasing acceptance. Following surgical and radiotherapy evi-dence illustrating the potential for cure in OMD [1–4] and the
advent of new radiotherapy technologies and techniques, the inter-
est amongst radiation oncology (RO) professionals for treating
OMD with curative intent has continuously been growing, even if
some remain hesitant regarding wide-spread implementation until
additional evidence across disease sites becomes available [5–8].
Although data from randomised phase II trials of stereotactic body
radiotherapy (SBRT) are emerging for several primary tumour sites
[9–13], there is not yet randomised phase III evidence on the
158 ESTRO-ASTRO OMD consensus documentefficacy of SBRT, or more generally, curative intent MDRT, for OMD.
In addition, uncertainties remain regarding the exact definition of
OMD [14,15], and reporting outcomes of patients with OMD is
far from standardised, making cross-trial comparisons difficult.
Acknowledging the urgent need for standardisation within the
RO community to advance science and clinical patient care in this
important area, ESTRO (European Society for Radiotherapy and
Oncology) and ASTRO (American Society for Radiation Oncology)
launched a collaborative project to develop consensus on patient
identification and treatment of OMD. The work was performed
by a group of clinical experts from Europe and the US, mandated
by the respective scientific councils and boards of both societies.
This consensus paper analyses the prevailing definitions of pre-
dominantly extra-cranial OMD and factors that may affect these
definitions. Based on a systematic literature review and using a
Delphi consensus process, agreement on statements pertaining to
6 different topics related to OMD (disease characteristics, disease
burden, timing of OMD, relation to other treatments, endpoints
and impact of technology) is presented, along with a critical dis-
cussion based on the evidence gathered in the review. Recommen-
dations for improving future evidence generation and reporting are
formulated.Materials and methods
Literature review
A systematic literature review, following PRISMA principles
[16], was performed in Medline, Embase and the Cochrane library.
The initial search performed in September 2018 included all publi-
cations until that date, reporting outcome of patients with limited
metastatic burden and treated with stereotactic radiotherapy. It is
acknowledged that this scope excluded studies of non-stereotactic
based curative intent MDRT which may also be of interest. To
address limitations inherent to the rapid rate of new publications,
we agreed a priori to repeat the systematic review for studies pub-
lished between September 2018 and August 2019 to confirm
robustness of the consensus findings over the timeframe of the
process.
Retrospective and prospective series were included; reviews,
surveys, letters and abstracts were excluded. Non-randomised
reports including fewer than 50 patients treated with radiotherapy,
studies solely focusing on brain metastases, not reporting clinical
outcomes or solely covering non-English content were excluded
(Appendix A).
Screening and initial eligibility were addressed by two authors
(IK, DN), consulting others for disagreement resolution. All authors
reviewed a proportion of the selected full papers for compliance
with the inclusion criteria, and consistency of the data extraction
was ascertained using predefined templates. Subsequently, the
extracted evidence was analysed per topic: disease characteristics
(AMR, DG, CP); maximum disease burden (DN, DP); timing of OMD
development (MG, IK); relation of MDRT to other treatments (MH,
MS, JY); relevant endpoints reported (PI, UR) and impact of tech-
nology on indication and outcome (YL, WW). The results were dis-
cussed amongst all authors and informed the Delphi process.
Evidence retrieved in August 2019 was made available to support
the final description.Delphi survey
The Delphi consensus process (Appendix B) used methods pre-
viously described [17]. Consensus was defined a priori as 75%
agreement on any statement. Three rounds of consensus-building
were conducted using anonymous, online surveys (SurveyMon-
key). Prior to the first round, participants assembled a list of 16key questions (KQs, Table 1) pertaining to SBRT for oligometastases
and conform the 6 topics addressed in the systematic review.Results
Literature review and Delphi process
The systematic literature review identified 7030 potential pub-
lications in the first search and 385 in the second search, which
resulted, after screening and assessment, in 75 and 23 papers
respectively. After excluding one interim report identified in the
first round, published with final results in the second round, the
number of publications amounted to 97 (for full list, see Appendix
C). As illustrated in Fig. 1, there was a gap of more than 10 years
between the initial publication of Hellmann and Weichselbaum
and the publications fitting our search. The vast majority were ret-
rospective reports, either single-centre (n = 50) or multicentre
(n = 23). Six papers reported single-arm prospective cohorts; while
studies reporting a phase I, II and phase II-randomised design
accounted for 9, 5 and 4 publications, respectively.
There was large heterogeneity in study design: studies either
reported on a variety of primary tumours or focused on specific
tumour entities (e.g. prostate or lung) or metastatic sites (e.g.
lymph nodes or lung metastases). The OMD definitions used across
publications were equally variable (Table 2). The steps leading to
the consensus statements are illustrated in Fig. 2.Consensus statements and literature discussion
Table 1 lists the KQs and the consensus reached for each of
them, below the different statements are organised in common
concepts, commented by the experts and illustrated with the liter-
ature. The numbering follows that of the table.Statements 1 and 2:
The concept of OMD is independent of primary tumour type and
histology (Statement 1) and of the metastatic site(s) (Statement 2).
Although some papers focused on a specific primary tumour
type, most frequently colorectal, prostate and lung [10,18–51],
many diseases have been examined including unknown pri-
mary. Disease-specific histology has not been specified in many
articles, adenocarcinoma was however frequently recorded.
There was broad agreement that prognosis can differ substan-
tially based on the primary tumour, and that some tumour
types are less likely to be oligometastatic (e.g., SCLC). However,
is was agreed that the concept of an intermediate state of OMD
with limited metastatic capacity is independent of the type of
primary tumour [12].
Among reports focusing on site of metastases [52–78], lung,
liver and lymph nodes are most widely studied. Patients with
intracranial metastases are most commonly reported separately
from extra-cranial OMD, but these patients should be included
in future OMD studies.
There was agreement that prognosis may vary based on the
metastatic site. However, apart from patients with diffuse dis-
ease such as malignant pleural effusions, leptomeningeal or
peritoneal carcinomatosis, the concept of OMD is not consid-
ered to depend on the metastatic site.
Statement 3:
There are currently no validated biomarkers that differentiate
between the oligometastatic and the polymetastatic state.
Table 1
Key questions per topic addressed in the Delphi process, with level of consensus obtained in the different Delphi rounds.
Key questions and consensus statements Level of consensus Delphi Round
Disease characteristics
KQ 1: Is the concept of OMD depending on the type of primary tumour?
No, the concept of OMD is not related to a specific primary 100% (11/11) Delphi round 3
KQ 2: Is the concept of OMD depending on the site of metastasis?
No, the concept of OMD is not dependent on the site of the metastasis 100% (10/10) Delphi round 3
KQ 3: Are there any validated biomarkers that are indicative of an oligometastatic state?
No, there are currently no validated biomarkers that differentiate between the oligometastatic and the
polymetastatic state
100% (11/11) Delphi round 1
KQ 4: Are there any minimum imaging requirements to define an oligometastatic state?
Yes, diagnostic imaging should be performed using whichever modalities are adequate to image sites of
common metastases and to detect small lesions for that histology.
CT scan of the chest/abdomen/pelvis and MRI of the brain or spine, if indicated, is recommended.
PET/CT is recommended
91% (10/11)
91% (10/11)
82% (9/11)
Delphi round 2
Delphi round 2
Delphi round 2
Maximum disease burden
KQ 5: Is OMD defined by a maximum number of lesions and/or sites?
No, the possibility to safely deliver curative intent metastasis-directed radiotherapy determines the
maximum number
82% (9/11) Delphi round 2
KQ 6: Is maximum disease burden defined by technically safe treatment with curative intent?
Yes, but it is recognized that the ability to treat safely does not mean that one should treat.
Regardless of the number of metastases the patient should not be treated if not safe
90% (9/10)
100% (10/10)
Delphi round 3
Delphi round 3
Timing of OMD development
KQ 7: Are there different types of OMD related to the time of diagnosis of primary tumour?
Yes, there are different types of OMD, defined by the timing of OMD vs. primary tumour 91% (10/11) Delphi round 1
KQ 8: Are there different types of OMD related to the onset of metastases?
Yes, different states of systemic therapy induced OMD are reported in the literature 100% (11/11) Delphi round 1
Relation of metastasis-directed radiotherapy to other treatments
KQ 9: Should there be a disease-free interval after treatment of the primary tumour?
No, a disease-free interval is not mandatory to define OMD 91% (10/11) Delphi round 1
KQ 10: Should there be a treatment-free interval after systemic treatment of metastases?
No, a treatment-free interval is not mandatory to define OMD 100% (11/11) Delphi round 1
KQ 11: When is progression under systemic therapy considered oligo-metastatic?
‘Oligoprogression’ should be defined differently than ‘oligometastasis’.
There is no consensus whether or not the criteria for number of disease sites or locations should differ
90% (9/10)
50% (5/10)
Delphi round 3
Not reached
KQ 12: Are patients who had polymetastatic disease and have induced OMD after systemic therapy considered
oligo-metastatic?
Yes, patients with prior polymetastatic disease can become OM after successful systemic therapy 82% (9/11) Delphi round 1
Endpoints
KQ 13: Does the risk for toxicity of metastasis-directed radiotherapy impact the indications for
treatment of OMD?
Yes, the risk of toxicity impacts treatment indications
100% (11/11) Delphi round 1
KQ 14: Which endpoints are important for OMD?
Following endpoints are considered important:
- overall survival
- disease-free or progression-free survival (including time to recurrence, progression or death)
- local control
- toxicity
- quality-of-life
- patient-reported outcomes
- cost
- delay or deferral of systemic treatment
- ability to stay on the same systemic treatment
91% (10/11)
100% (11/11)
91% (10/11)
100% (11/11)
82% (9/11)
82% (9/11)
82% (9/11)
82% (9/11)
80% (8/10)
Delphi round 2
Delphi round 2
Delphi round 2
Delphi round 2
Delphi round 3
Delphi round 2
Delphi round 2
Delphi round 2
Delphi round 3
Impact of technology on indication and outcome
KQ 15: Does the availability of technology impact the indications for treatment of OMD?
Yes, although technology per se does not impact the indications, adequate technology and/or
techniques (e.g. SBRT) are a minimum requirement to treat OMD
82% (9/11) Delphi round 1
KQ 16: Is there a minimum BED (a/b = 10) required to achieve local control of OMD?
Yes, although likely there will be variation as the data emerge, the goal is control of the targeted
metastasis, for which the data support a higher biologic equivalent dose (such as >100 Gy BED10)
90% (9/10) Delphi round 2
Abbreviations:
KQ: Key question; OMD: oligometastatic disease; CT: computed tomography, MRI: magnetic resonance imaging, PET: positron-emission tomography; SBRT: sterotactic body
radiotherapy; BED: biologically effective dose
Note: The order of the key questions and of the resulting statements presented here reflects the structure per topic used in the Delphi process. In the manuscript, the
statements have been reorganised following their content and discussion.
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research area, with preclinical and translational studies assess-
ing blood-based biomarkers such as microRNA expression and
circulating free DNA; tissue-based biomarkers such as muta-
tional status and intratumoural heterogeneity; and radiomic
parameters [79–82]. Ideally, integration of these categories of
biomarkers into a multi-systems predictions model will lead
to a more precise algorithm for defining OMD than the cur-rently most often used number of metastatic lesions, and thus
aid in assigning the appropriate treatment.
Statement 4:
Diagnostic imaging should be performed using whichever
modalities are most adequate to image sites of common metas-
tases and to detect small lesions for that histology.
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Fig. 1. Number of publications per year and per type, selected in both SLR searches, since the publication of Hellman andWeichselbaum in 1995 [6]. Note: Reports on interim
results were not included.
160 ESTRO-ASTRO OMD consensus documentMulti-modality diagnostic imaging was used for the evaluation
of metastatic disease in most studies reviewed [47]. Although
several studies did not specify modalities used in OMD workup
[32,83], in areas of focused disease-site evaluations, highly
specific imaging was utilized (e.g., contrast-enhanced bi-
phasic liver CT for liver metastases [30], PSMA-PET for prostate
OMD [37]).
While there was no consensus to recommend specific imaging
modalities as a requirement for OMD workup, there was con-
sensus to recommend PET/CT, contrast-enhanced chest/abdom-
inal and pelvis CT scans, and/or MR brain or spine (when
indicated) for diagnostic evaluation. Further, reflective of the
future development of imaging technologies in certain areas,
there was consensus to recommend any validated imaging
modalities that adequately image sites of common metastasis
and to detect small lesions.
Statements 5, 6, and 13:
The feasibility of safely delivering curative intent MDRT deter-
mines the maximum number of lesions and sites that can be treated
with radiotherapy* in OMD. The ability to safely treat all
oligometastases with radiotherapy does not mean that one should
treat every patient irrespective of other prognostic factors (State-
ment 5). Regardless of the number of metastases, the risks and
benefits of MDRT should be balanced carefully in all oligometa-
static patients (Statement 6). The risk of toxicity impacts treatment
indications for OMD (Statement 13).
*Italicized text added after consensus was formed to provide
needed clarification highlighted during the review process.
Reviewing the literature, ‘up to 5’ and ‘up to 3’ oligometastatic
lesions are the most commonly-used quantitative definitions.
Similar limits were sometimes placed on the maximum number
of metastases per organ (Table 2). However, studies differ on
whether the primary tumour is counted (for patients with syn-chronous oligometastases), on imaging modalities and their
sensitivity used for patient staging, and whether regional lymph
node targets are counted as individual targets or grouped
together. Several papers have no maximum number of lesions
defined, nor report median or range.
At present, there is no biological evidence supporting the max-
imal number of metastases, or the maximal lesion size, that can
be treated to provide clinical benefit. In treatment planning, the
upper limit of technically safe curative intent MDRT is not well-
studied. No studies that met the review criteria attempted to
determine the maximum lesion number or size. A maximum
cut-off size of 5 cm is sometimes used, but larger lesions may
be treatable depending on location and with careful attention
to dose constraints, recognizing size is prognostic for control
in multiple studies [26,27,41,83,84].
In the absence of sensitive and specific biomarkers, with num-
ber of metastatic lesions and organs commonly being used as
surrogates for patient selection, the consensus obtained
regarding maximum number of lesions that can be considered
as OMD was that the maximum number must be limited by
the ability to deliver safe, curative intent MDRT, which can
vary on a case-by-case basis. This agrees with surgical strate-
gies where technical resectability, not a fixed number of
metastases, decides for or against a metastasis-directed treat-
ment strategy. Similarly, the consensus also excludes patients
who may have few lesions, but where the safety of delivering
an adequate dose is questionable. Recognizing future tech-
nologies may increase the feasibility of targeting more wide-
spread disease, there was also consensus that the technical
ability to treat numerous lesions safely should not lead to
expanded selection criteria off-protocol or without clinical
data to support it.
While not formally concluded from the Delphi consensus pro-
cess, to date, very little of the extra-cranial data reviewed
includes more than 5 sites. For this reason, the authors agreed
that 5 lesions should be considered an upper bound off-
Table 2
OMD definitions used across publications.
Oligometastatic disease (OMD)
Many refer to the original definition of Hellman and Weichselbaum [6]: An intermediate state between local and
systemic disease, where radical local treatment of the primary cancer and all metastatic lesions might have a
curative potential
[19,21,25,29,32,34,38,51,57,58,61,64,65,73–
75,78,83,87,92,99,100,104–111]
+ Outcome
An intermediate state in which local or treated metastasis control may yield improved systemic control [39,66]
+ Disease burden
Limited number of metastases: oligometastatic is defined as a small number of low volume metastases, 5 or less,
3 or less
[22,23,35,42,45,70,112–114]
Limited number of sites/regions [31,71]
Single or limited number of organs [115]
Limited number of metastases and sites [68,69]
Limited number of distant metastatic regions (typically 5) that contain the primary tumor [77]
+ Disease type
More indolent disease, tumors featuring limited metastatic capacity [26,62,84,116]
Specified for certain organ: limited pulmonary dissemination, limited number of nodal recurrences (in prostate
cancer; typically, 3 or 5)
[11,44,55]
+ Alternative hypotheses
OMD represents the transition between localized and widespread systemic disease OR the clinical manifestation
of detectable lesions in a setting of widespread occult disease
[117]
Synchronous OMD
OMD at the time of initial diagnosis, primary tumor and limited number of metastases detected simultaneously [25,52]
+ Disease load
5 metastatic lesions with active primary lesions [78]
Metachronous OMD, often used interchangeably with Oligo-Recurrence
Oligometastatic recurrence during the course of disease at least three months after the initial diagnosis
(‘metachronous’), as a state of metachronous limited recurrence
[25]
Many refer to the original definition of Niibe and Hayakwa [85]: Metastases detected while the primary tumor is
controlled and that can be treated with local therapy.
[52,71,89,104,115]
+ Outcome
Achieve control of metastatic sites [104]
+ Disease load
One to several metastatic recurrences in one to several organs [53]
<5 new metastases in an otherwise well-controlled (primary) disease state [39,78]
A limited number of distant metastatic regions (typically 5) that contain the primary tumor [77]
+ Disease type
After primary prostate cancer treatment: 3 metastases [11]
Oligo-Progression
Few lesions progress on a background of widespread but stable metastatic disease [83]
+ Link with other therapies
Progression occurs in a limited number of tumors/metastases while the majority of other metastases are
responding or stable while on a systemic treatment strategy
[41,48,61]
Progression occurs after a cytoreductive treatment [67]
Progression while other sites including the primary disease remain stable on systemic treatment or observation [113]
Resistant clones can result in isolated progression [42]
+ Disease load
<5 enlarging metastases in an otherwise well-controlled disease state [39]
<5 sites of metastatic disease progression while other sites including primary remain stable on systemic
treatment
[113]
3–5 slowly progressive metastases [36,48]
Oligo-Persistence
Persistent disease after systemic therapy [67]
+ Disease load
<5 persistent lesions after systemic therapy [39]
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treatment factors, as well as appropriateness of treatment
(e.g., depending on performance status, pace of disease and
likelihood of diffuse occult metastases) should be considered
when taking decisions for individual patients. Importantly,
treatment-related death [12,69,70,77,85] and other serious tox-icities [59,60,65,72] are uncommon, but they have been
reported. The utilization and benefits of MDRT for OMD must
be determined by the therapeutic ratio of efficacy to toxicity.
Normal tissue toxicity is dependent on the anatomic location
of disease receiving therapy and should be measured with stan-
dard toxicity metrics.
Fig. 2. Different steps and timing of the literature review and Delphi consensus. Note: Interim results were excluded within one SLR, but not across the SLR rounds.
Abbreviations: SLR: systematic literature review; OMD: oligometastatic disease; RT: radiotherapy.
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OMD is differentiated into synchronous versus metachronous
states, defined by the interval between primary cancer diagnosis
and development of OMD (Statement 7). A disease-free interval
(DFI) is not mandatory to define OMD (Statement 9).
The main categorization in the literature reviewed was syn-
chronous versus metachronous (often referred to as oligorecur-
rent) OMD, typically differentiated by a time interval of 3–
6 months between primary cancer diagnosis and development
of OMD (Table 2). When reported, the primary tumour had fre-
quently been treated with curative intent in metachronous
OMD. A locoregionally controlled primary tumour is not a pre-
condition but should be considered a prognostic parameter
which is critical to report specifically. Some studies reported a
better prognosis for metachronous OMD [28,86], but this was
not consistently observed [25,74].
Though both synchronous and metachronous metastases are
considered OMD, the prognosis, options for treatment and risk
of occult disseminated metastases of these patients can differ,
with the length of the DFI appearing to have a prognostic
impact [46,69,87]. While concerns were raised about prognosis
of metastases developing shortly after primary cancer treat-
ment, uncertainty remains regarding the importance of the
DFI, as data are lacking to support a consensus for minimum
DFI in the definition of metachronous OMD.
Statements 8, 11 and 12:
Different states of systemic therapy induced OMD are reported
in the literature, with inconsistent nomenclature and definitions
(Statement 8). Patients with prior polymetastatic disease can
become OM based on response to systemic therapy (Statement
12). There was no consensus on the criteria for a maximum num-ber of metastases or organs for systemic therapy induced OMD
(Statement 11).
There is growing but still limited evidence on the development
of OMD after systemic therapy for polymetastatic disease.
While it was agreed that originally polymetastatic disease that
becomes OMD should be defined as ‘induced OMD’, concerns
were raised on the difficulty in histopathologic confirmation
of polymetastatic disease, and the potential importance of local
tumour control. It was also cautioned that the treatment goal in
induced OMD may not be improved survival as polymetastatic
disease is generally considered ‘incurable’ for most malignan-
cies but may be improved progression-free survival (PFS),
quality-of-life (QoL) or local control (LC).
In the context of systemic therapy induced OMD, additional
conceptual states of OMD are described in the literature e.g.,
oligoprogressive or oligopersistent disease. However, defini-
tions of those terms varied in original research and in review
articles (Table 2) [88–91]. Oligoprogression on systemic therapy
is clearly a different clinical entity than OMD, with possibly
worse prognosis compared to de novo or isolated metastatic
disease [39,41,48,83,92], but with a treatment goal that may
be more focused on keeping patients on a current line of sys-
temic therapy, rather than ablation of the metastasis per se
[93].
Statement 10:
A treatment-free interval (TFI) is not mandatory to define OMD.
Similar as for DFI, the heterogeneous reporting of TFI and dis-
ease at initial presentation is observed in the literature.
There was consensus that the relation of OMD states to the
treatment status (during or after systemic therapy or after a
minimum DFI or TFI) is of paramount importance to defining
the relevant clinical scenario, but questions remain about these
Y. Lievens et al. / Radiotherapy and Oncology 148 (2020) 157–166 163multiple clinical situations where OMD can arise as above,
hence the multiple interpretations of ‘TFI’. In some OMD states,
TFI would have prognostic value (in the case of initially local-
ized disease), in others it would ideally be minimized in a treat-
ment course (in the case of initially polymetastatic disease).
Complete reporting of primary presentation and subsequent
systemic therapy is critical for future study.
Statement 14:
Overall survival (OS), disease-free survival (DFS) or PFS, LC, tox-
icity, QoL, patient-reported outcomemeasures, cost, delay or defer-
ral of systemic therapy and ability to stay on the same line of
systemic therapy are all considered important endpoints.
In the literature, efficacy of treatment for OMD is measured by
various parameters, OS, PFS, LC and toxicity being most fre-
quent. QoL and patient-reported outcome measures are infre-
quently identified based on our analysis of studies
represented in this paper’s literature review.
In the Delphi consensus, OS had the strongest support for being
critical to showing benefit of MDRT for OMD, followed - in
decreasing order - by PFS, LC, toxicity, QoL, patient-reported
outcome measures, cost, delay or deferral of systemic therapy,
and finally ability to stay on same systemic therapy without
change.
While international criteria have been proposed for endpoints
evaluating the benefit of oncology drugs (and support their
reimbursement), it is acknowledged that other endpoints may
also be important in the context of loco-regional oncology
interventions [94–96] and that the most adequate endpoint
may be dependent of the clinical situation.
Statements 15 and 16:
Although technology per se does not impact the indications,
adequate technology and/or techniques (e.g., SBRT or hypofrac-
tionated image-guided radiotherapy) are a minimum requirement
to treat OMD when pursuing curative intent (Statement 15).
Although there is a broad variation in the delivered doses being
reported, the goal is control of the targeted metastasis for which
the current data support a higher biologic equivalent dose (BED,
e.g., >100 Gy BED10) (Statement 16), when it can be safely
delivered.
The primary goal of delivering curative intent MDRT is to max-
imize tumour control while minimizing short and long-term
effects of radiation. Therefore, every effort should be made to
ensure precise delivery of radiotherapy using all available techno-
logical resources. More advanced technologies and/or techniques
that facilitate smaller set-up margins, without compromising
tumour coverage while limiting dose to normal tissues, have facil-
itated the increased interest in defining and treating OMD. Lack of
motion management use [52,63], planning target volume size
[23,63,84,97] and coverage [73,76] have been associated with
lower tumour control. Overall however, detailed reporting of plan-
ning constraints and protocol deviations is minimal in the litera-
ture reviewed, highlighting an area in need of improvement.
While there are not sufficient literature data to address dose
and BED by primary and in all relevant contexts, the convergence
of existing data highlighting improved LC of the targeted metasta-
sis with a minimum of 100 Gy BED10 makes this a goal when fea-
sible until further evidence emerges [23,35,44,52,63,67,73,78,98].
It is noted however that in sites where normal tissue constraints
make this infeasible near the bowel, great vessels or spinal cord,
lower BEDs have been associated with control [99,100] and future
studies may identify clinical scenarios where lower doses are ade-quate. Additionally, studies addressing systemic therapy induced
OMD used lower radiation doses compared to studies addressing
synchronous or metachronous OMD.Discussion
Increasing enthusiasm for and technology to support safe radi-
ation treatment of OMD has already led to a sharp increase in data
in this field, and more trials are rapidly accruing to define the role
of SBRT and other curative intent MDRT approaches in the context
of the actual standards of care, of new systemic treatment strate-
gies and compared to other local interventions. Meanwhile, this
systematic literature review demonstrated substantial heterogene-
ity amongst the SBRT publications in terms of patients included,
endpoints reported, and definitions used (Table 2). These findings
guided the development of key unanswered questions, leading to
consensus using the Delphi process. Key points, summarized in
Table 1, emphasize there are not yet adequate biomarkers, includ-
ing number of metastases, to conclude that primary tumour or
metastatic site, response to therapy, or DFI limits preclude a poten-
tial oligometastatic state. It is clear many of these factors impact
prognosis, however, explicitly describing the patient population
studied and outcomes using consistent language is paramount to
future progress.
In the absence of relevant biomarkers, the OMD state is cur-
rently defined based on imaging and clinical judgement. To homo-
genise diagnostic requirements, the EORTC (European Organisation
for Research and Treatment of Cancer) Imaging Group has pro-
posed minimal criteria for diagnostic imaging to define OMD
[101]. To address the heterogeneity and uncertainties of OMD in
its clinical implementation, ESTRO and EORTC have also jointly ini-
tiated OligoCare under the E2-RADIatE platform (EORTC-ESTRO
RADiation InfrAstrucTure for Europe, NCT03818503). This interna-
tional prospective registry trial aims to identify patient, tumour,
staging, and treatment characteristics that impact OS of patients
treated with radical radiotherapy for OMD. The inclusion criteria
are broad to reflect the diversity of daily clinical practice and to
allow the identification of relevant prognostic and predictive fac-
tors. In this frame, an OMD characterization system has been
developed to classify distinct oligometastatic states and assign a
consensus nomenclature [93]. The authors herein endorse the Oli-
goCare classification consensus and encourage using this approach
to unify definitions internationally.
The fast pace of clinical data emerging in this field limits the
output of systematic literature review. Although randomised phase
III evidence is lacking, recent randomised phase II trials have
shown the potential of SBRT to improve survival of patients with
OMD [9,10,12] and multiple randomized trials are expected in
the next few years. A recent review reports 64 ongoing trials study-
ing ablation of OMD, activated and accruing through February
2019 [102]. Over half were phase II (n = 35), however, 17 random-
ized controlled trials were noted. All are encouraged to build on
these promising data by continuing to enrol in ongoing random-
ized trials. In addition, besides the further need for randomised
data, it has been recognised that randomised evidence is difficult
to generate and by itself insufficient to fully define the benefit of
new radiotherapy indications, especially if set against the back-
ground of a continuously changing multidisciplinary environment,
as is the case for MDRT for OMD [96,103]. This stresses the need for
a blended approach to evidence generation, of real-world data – all
or not collected in the context of a coverage with evidence pro-
gramme –, together with randomised trials to further shed light
on the benefit of curative intent radiotherapy, and of other local
MDRT approaches such as surgery and radiofrequency ablation,
used in the context of OMD.
164 ESTRO-ASTRO OMD consensus documentIn conclusion, considerably more data are needed to define the
optimal patient selection for SBRT or otherwise curative intent
MDRT for OMD. Synchronous and metachronous OMD are cur-
rently best defined as distinct disease states. Others such as olig-
orecurrence, -progression and -persistence are plausible
scenarios where clinically evident disease may represent the true
disease state as opposed to impending wide spread disease. Based
on ongoing trials it is clear that further complexity will be added
regarding the use of concurrent systemic therapy or immunother-
apy [102]. It is therefore critical that authors and editors are expli-
cit about inclusion criteria and definitions, endpoints and toxicity,
while continuing to generate evidence on this complex and evolv-
ing clinical indication. Additional data are needed to determine the
value of MDRT for selected cohorts of patients identified by key
clinical features and/or extent and timing of OMD. Clinical judge-
ment and individual patient factors remain key features of defining
OMD. Future prospective studies should consider stratifying
patients into different categories, e.g., such as will be performed
in the context of the OligoCare trial. Meanwhile, based on the avail-
able evidence, indications for curative intent radiotherapy of OMD
can be defined as 1 to 5 metastatic lesions, with a controlled pri-
mary tumor being optional, but where all metastatic sites must
be safely treatable.Disclaimer
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